Alfa Aesar Acquires Biomedical Technologies, Inc.
News Sep 19, 2013
Alfa Aesar has announced that it has completed the purchase of Biomedical Technologies, Inc. (BTI) of Stoughton, Massachusetts.
BTI has been manufacturing life science research products for more than 30 years, with a commitment to its customers of technology, quality and value.
Its product line includes specialty proteins, cell culture additives and highly specific immunoassay tools, which Alfa Aesar will continue to build upon as it expands its portfolio of unique biochemical products for the researcher.
Commenting on the transaction, Julie Butterfield, General Manager of Alfa Aesar said: “Alfa Aesar is already known for providing researchers access to unparalleled expertise and supply of a wide variety of inorganic and organic chemicals used in both academia and industry. For our customers in the life sciences, we are committed to enhancing our offer in the biochemical arena through a selection of methodically chosen products that complement our current portfolio and build on our core competencies. The acquisition of BTI brings protein research and characterization, all types of profiling tools, and certain separation technologies and provides opportunities for Alfa Aesar to leverage BTI’s manufacturing capabilities to enhance its overall product offering.”
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.